Kai H, Sugimachi K, Tamada R, Takenaka K, Inuzuka S, Natsuda Y, Taguchi J, Kobayashi M, Kaneko T, Mitarai Y
Second Department of Surgery, Faculty of Medicine, Kyushu University.
Jpn J Antibiot. 1988 Mar;41(3):322-30.
We conducted clinical studies on the efficacy and safety of cefbuperazone (CBPZ) on surgical infections with the following results. 1) In evaluable 32 patients, CBPZ was evaluated to be clinically effective in 23 (71.9%) and the efficacy rate was better in those who were administered 4 g/day of CBPZ (87.5%, 14/16) than in those who were given 2 g/day (57.1%, 8/14). 2) Antibacterial activity of CBPZ was evaluated in 41 isolated bacterial strains. Pathogen eradication rate by bacterial species was 75.6% (31/41). CBPZ exerted excellent antibacterial effects on Escherichia coli (100%, 8/8) and anaerobic bacteria such as Bacteroides (88.9%, 8/9). Resistant bacteria to CBPZ were Enterococcus faecalis and Pseudomonas aeruginosa. 3) No serious side effects were noted in any of the 34 patients who entered in this study. Abnormal laboratory test results were noted in 2 patients (5.9%) and they were transient elevation of transaminases and alkaline phosphatase. From the results shown above, CBPZ appears to be a highly useful antibiotic for the treatment of surgical infection.
我们对头孢哌酮（CBPZ）治疗外科感染的有效性和安全性进行了临床研究，结果如下。1）在可评估的32例患者中，CBPZ临床有效率为71.9%（23/32），每日给予4g CBPZ的患者有效率（87.5%，14/16）高于每日给予2g的患者（57.1%，8/14）。2）对41株分离菌株评估了CBPZ的抗菌活性。按菌种计算的病原菌清除率为75.6%（31/41）。CBPZ对大肠杆菌（100%，8/8）和拟杆菌等厌氧菌（88.9%，8/9）具有优异的抗菌效果。对CBPZ耐药的细菌为粪肠球菌和铜绿假单胞菌。3）本研究纳入的34例患者均未出现严重副作用。2例患者（5.9%）出现实验室检查结果异常，表现为转氨酶和碱性磷酸酶短暂升高。根据上述结果，CBPZ似乎是治疗外科感染的一种非常有用的抗生素。
